Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort
Danja Sarink, Helena Schöck, Theron Johnson, et al.
Cancer Prevention Research (2017) Vol. 10, Iss. 9, pp. 525-534
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption
Hideki Kitaura, Aseel Marahleh, Fumitoshi Ohori, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5169-5169
Open Access | Times Cited: 257
Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss
Jinhu Xiong, Keisha M. Cawley, M. Piemontese, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 119
RANKL and RANK: From Mammalian Physiology to Cancer Treatment
Shuan Rao, Shane J. F. Cronin, Verena Sigl, et al.
Trends in Cell Biology (2017) Vol. 28, Iss. 3, pp. 213-223
Closed Access | Times Cited: 78
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment
Peter A. van Dam, Yannick Verhoeven, Xuan Bich Trinh, et al.
Critical Reviews in Oncology/Hematology (2018) Vol. 133, pp. 85-91
Open Access | Times Cited: 66
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
Jie Ming, Shane J. F. Cronin, Josef Penninger
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 56
Molecular Mechanisms Leading from Periodontal Disease to Cancer
Bartosz Kamil Sobocki, Charbel A. Basset, Bożena Bruhn‐Olszewska, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 970-970
Open Access | Times Cited: 34
Oncobiology and treatment of breast cancer in young women
Rakesh Kumar, Catarina Abreu, Masakazu Toi, et al.
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 3, pp. 749-770
Closed Access | Times Cited: 27
Progesterone, progestins and the breast in menopause treatment
Anne Gompel, Geneviève Plu‐Bureau
Climacteric (2018) Vol. 21, Iss. 4, pp. 326-332
Closed Access | Times Cited: 35
Prevention and Co-Management of Breast Cancer-Related Osteoporosis Using Resveratrol
Christine Meyer, Aranka Brockmueller, Constanze Buhrmann, et al.
Nutrients (2024) Vol. 16, Iss. 5, pp. 708-708
Open Access | Times Cited: 3
RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review
Peter A. van Dam, Yannick Verhoeven, Julie Jacobs, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 9, pp. 2183-2183
Open Access | Times Cited: 26
Association of SNP-SNP Interactions Between RANKL, OPG, CHI3L1, and VDR Genes With Breast Cancer Risk in Egyptian Women
Olfat Shaker, Mahmoud A. Senousy
Clinical Breast Cancer (2018) Vol. 19, Iss. 1, pp. e220-e238
Closed Access | Times Cited: 22
Hormone and receptor activator of NF-κB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women
Rachel L. Mintz, Mei Wang, Shuai Xu, et al.
Breast Cancer Research (2022) Vol. 24, Iss. 1
Open Access | Times Cited: 10
Risk association of RANKL and OPG gene polymorphism with breast cancer to bone metastasis in Pashtun population of Khyber Pakhtunkhwa, Pakistan
Faiza Hayat, Najeeb Ullah Khan, Aakif Ullah Khan, et al.
PLoS ONE (2022) Vol. 17, Iss. 11, pp. e0276813-e0276813
Open Access | Times Cited: 8
RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer
Annika Behrens, Lena A. Wurmthaler, Felix Heindl, et al.
Geburtshilfe und Frauenheilkunde (2023) Vol. 84, Iss. 01, pp. 77-85
Open Access | Times Cited: 4
Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort
Danja Sarink, Helena Schöck, Theron Johnson, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 12
Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women
Adetunji T. Toriola, Catherine M. Appleton, Xiaoyu Zong, et al.
Cancer Prevention Research (2018) Vol. 11, Iss. 12, pp. 789-796
Open Access | Times Cited: 12
Serum osteoprotegerin levels and mammographic density among high-risk women
Olivia Moran, Tasnim Zaman, Andrea Eisen, et al.
Cancer Causes & Control (2018) Vol. 29, Iss. 6, pp. 507-517
Closed Access | Times Cited: 8
Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case–Control Analysis Nested within the Nurses' Health Study II
Joanne Kotsopoulos, Emma E. McGee, Susana Lozano-Esparza, et al.
Cancer Epidemiology Biomarkers & Prevention (2020) Vol. 29, Iss. 6, pp. 1264-1270
Open Access | Times Cited: 8
Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort
Danja Sarink, Jiaxi Yang, Theron Johnson, et al.
Cancer Epidemiology Biomarkers & Prevention (2019) Vol. 28, Iss. 10, pp. 1746-1754
Open Access | Times Cited: 7
The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer
Peter A. van Dam, Yannick Verhoeven, Xuan Bich Trinh
Advances in experimental medicine and biology (2020), pp. 53-62
Closed Access | Times Cited: 6
Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation
Sarah Sohyun Park, Aleksandra Uzelac, Joanne Kotsopoulos
Hereditary Cancer in Clinical Practice (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 4
Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
Tasnim Zaman, Ping Sun, Steven A. Narod, et al.
Oncotarget (2019) Vol. 10, Iss. 25, pp. 2475-2483
Open Access | Times Cited: 5
RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
Hong Wang, Reading Ashton, Jonathan A. Hensel, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 12, pp. 2585-2597
Open Access | Times Cited: 5
RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer
Annika Behrens, Lena A. Wurmthaler, Felix Heindl, et al.
TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 02, pp. 112-119
Open Access
RANKL regulates differentially breast cancer stem cell properties through its RANK and LGR4 receptors
Alejandro Ordaz-Ramos, Jorge Yassen Díaz-Blancas, Aketzalli Martínez-Cruz, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2024) Vol. 1872, Iss. 2, pp. 119888-119888
Closed Access
Page 1 - Next Page

Scroll to top